POTENTIAL SENSITIVITY TO METFORMIN OF THE DIABETICS SUFFERING AND NOT SUFFERING WITH CANCER: A PHARMACOGENETIC STUDY

Cover Page

Abstract


The group (totally156 postmenopausal women) used for the study of ‘standard’ (S) and ‘associated’ (A) genetic markers of potential sensitivity to metformin (MF) consisted of 37 healthy females, 32 — with diabetes (DM) without cancer, 64 cancer patients with DM, and 23 cancer patients without DM. No significant difference in carrying of S-polymorphisms was found between DM patients without and with cancer. In cancer patients without DM most characteristic data regarding potential MF-response were detected with polymorphisms of STK11 gene while data on OCT1_rs622342 and OCT1_R61C variants showed opposite trends. In regard of A-markers, the tendency to the more often finding of GC genotype of OLR1_G501C in DM patients carrying ‘MF-positive’ variant of OCT1_R61C deserves to be underlined. In patients with new-onset diabetes who carried S-markers of potential response to MF higher insulin resistance (OCT1_R61C and OCT1_rs622342) as well as lower estradiolemia (STK11 and C11orf65) were discovered. Thus, according to genetic S-criteria of sensitivity to MF, DM patients with and without cancer differ in lesser degree than they differ from cancer patients without DM. It can not be excluded, that The efficiency of such criteria might be increased due to combination with A-markers and certain hormonal-metabolic indices.

 


About the authors

L. M. Berstein

N.N. Petrov Research Institute of Oncology, St.Petersburg, Russian Federation

Author for correspondence.
Email: levmb@endocrin.spb.ru

Russian Federation PhD, professor, Head of the Laboratory of Oncoendocrinology of FSBI “N.N. Petrov Research Institute of Oncology”. MD, professor, head of Laboratory of Oncoendocrinology, Federal State Budget Institution “N.N. Petrov Scientific Research Institute of Oncology” Address: 68, Leningradskaya Street, Pesochnii, St. Petersburg, RF, 197758; tel.: +7 (812) 439-9536

A. G. Ievleva

N.N. Petrov Research Institute of Oncology, St.Petersburg, Russian Federation

Email: aglayai@inbox.ru

Russian Federation MD, research scientist of Molecular Oncology Laboratory of FSBI “N.N. Petrov Research Institute of Oncology”. Address: 68, Leningradskaya Street, Pesochnii, St. Petersburg, RF, 197758; tel.: +7 (812) 439-9528

D. A. Vasil'ev

N.N. Petrov Research Institute of Oncology, St.Petersburg, Russian Federation

Email: dvasilyev@hotmail.com

Russian Federation MD, senior research scientist of Oncoendocrinology Laboratory of FSBI “N.N. Petrov Research Institute of Oncology”. Address: 68, Leningradskaya Street, Pesochnii, St. Petersburg, RF, 197758; tel.: +7 (812) 439-9536

I. M. Kovalenko

N.N. Petrov Research Institute of Oncology, St.Petersburg, Russian Federation

Email: ira_dv@mail.ru

Russian Federation research scientist of Oncoendocrinology Laboratory of FSBI “N.N. Petrov Research Institute of Oncology”. Address: 68, Leningradskaya Street, Pesochnii, St. Petersburg, RF, 197758; tel.: +7 (812) 439-9536

E. N. Imyanitov

N.N. Petrov Research Institute of Oncology, St.Petersburg, Russian Federation

Email: evgeny@imyanitov.spb.ru

Russian Federation PhD, professor, Head of the Department of Tumor Growth Biology of FSBI “N.N. Petrov Research Institute of Oncology”. Address: 68, Leningradskaya Street, Pesochnii, St. Petersburg, RF, 197758; tel.: +7 (812) 439-9528

References

  1. Dedov I.I., Shestakova M.V. Sakharnyi diabet: diagnostika, lechenie, profilaktika [Diabetes: Diagnostics, Treatment, Prevention]. Moscow, MIА, 2011. 803 p.
  2. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33 (7): 1674–1685.
  3. Bershtein L.M. Diabetes, obesity and cancer incidence: the risks and antiriski. Diabetes mellitus = Diabetes mellitus. 2012; 4: 81–88.
  4. Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012; 2 (9): 778–790.
  5. Ong C.R., Molyneaux L.M., Constantino M.I., Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care. 2006; 29 (10): 2361–2364.
  6. Becker M.L., Visser L.E., van Schaik R.H., Hofman A., Uitterlinden A.G., Stricker B.H. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009; 9 (4): 242–247.
  7. Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann. Med. 2012; 44 (2): 119–129.
  8. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K. Bellenguez C., Spencer C.C. et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 2011; 43 (2): 117–120.
  9. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., Steinkampf M.P. et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 2008; 93 (3):792–800.
  10. Le T.N., Nestler J.E., Strauss J.F. 3rd, Wickham E.P. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol. Metab. 2012; 23 (1): 32–40.
  11. Thameem F., Puppala S., Lehman D.M., Stern M.P., Blangero J., Abboud H.E., Duggirala R., Habib S.L. The Ser(326)Cys polymorphism of 8-oxoguanine glycosylase 1 (OGG1) is associated with type 2 diabetes in Mexican Americans. Hum. Hered. 2010; 70 (2): 97–101.
  12. Ulybina Yu.M., Imyanitov E.N., Vasil'ev D.A., Bershtein L.M. Polymorphic markers of genes determining violations zhirouglevodnogo exchange and insulin resistance in patients with cancer. Mol. biol. = Molecular biology. 2008; 42(6): 947–956.
  13. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7): 412–419.
  14. Samarajeewa N.U., Ham S., Yang F., Simpson E.R., Brown K.A. Promoter-specific effects of metformin on aromatase transcript expression. Steroids. 2011; 76 (8): 768–771.

Statistics

Views

Abstract - 188

PDF (Russian) - 72

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies